Bionomous SA

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Bionomous SA - overview

Established

2019

Location

Fribourg, -, Switzerland

Primary Industry

Medical Devices & Equipment

About

Based in Switzerland, Bionomous Sàrl operates in the life sciences sector, specializing in automating the screening and sorting of small biological entities through advanced technology solutions. Bionomous SA, founded in 2019 in Fribourg, Switzerland, focuses on the automation of biological entity handling. The company has engaged in two funding rounds, with the most recent being a Series A round on January 20, 2023, where it raised USD 2. 7 mn led by Nivalis Group SA along with participation from other investors.


The company was co-founded by Ana Ariza and Frank Bonnet, the latter also serving as CEO. Bionomous specializes in the automation of screening, sorting, and dispensing small biological entities, primarily through its flagship product, the EggSorter. This device, initially aimed at zebrafish embryo sorting, has expanded to include various organisms such as Xenopus oocytes and flower seeds, utilizing advanced micro-engineering and artificial intelligence for improved lab efficiency. Additionally, Bionomous provides LabSwipe, allowing customers to create custom image classification algorithms, addressing variability in manual selection criteria, targeting academic and research institutions in Europe and North America.


Bionomous generates revenue through the sale of its EggSorter and LabSwipe products to research institutions and laboratories. The company operates on a direct-to-consumer model, providing clients the option to purchase products outright with ongoing support and customization services. Typically, clients acquire the EggSorter for a fixed fee, which includes setup and training, while LabSwipe may be part of a package or offered via a subscription model based on usage needs, accommodating varying budget sizes for small-scale and larger research facilities. In January 2023, Bionomous SA raised USD 2.


7 mn, which will be allocated to boost production capacity and expand international product availability. The company is focusing on entering new markets across Europe and North America with plans to launch updated products that enhance their current automation solutions in the near future.


Current Investors

Venture Kick, Swiss ICT Investor Club, Nivalis Group SA

Primary Industry

Medical Devices & Equipment

Sub Industries

Molecular Science, Genetics & Gene Therapy, Medical Devices & Equipment

Website

www.bionomous.ch

Verticals

Artificial Intelligence, Manufacturing

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.